progressive multifocal leukoencephalopathy , PML (Abkürzung)
progressive multifocal leukoencephalitis

Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2.

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.

Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name?

Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2.

In June 2010, the first case report appeared of a progressive multifocal leukoencephalopathy being successfully treated with mefloquine.

Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial?

Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy.

Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy.

Seizures and their outcome in progressive multifocal leukoencephalopathy.

In 2009, voluntary U.S. market withdrawal after reports of progressive multifocal leukoencephalopathy.

Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection.

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy.

However, it has been associated with progressive multifocal leukoencephalopathy, a usually fatal viral infection of the brain, that may limit its use.

Progressive multifocal leukoencephalopathy in a child with hyperimmunoglobulin E recurrent infection syndrome and review of the literature.

New insights into progressive multifocal leukoencephalopathy.

Review of progressive multifocal leukoencephalopathy and natalizumab.

Support forum to educate, inform and inspire persons with progressive multifocal leukoencephalopathy and their families.

Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy.

The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology.

Progressive multifocal leukoencephalopathy: its pathological features.

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.

The good news, doctors say, is that most patients who took Tysabri alone and only since November are unlikely to develop progressive multifocal leukoencephalopathy.

Progressive multifocal leukoencephalopathy is a usually fatal infection of the brain that occurs rarely with this and other immunosuppressive drugs.

No cases of PML (progressive multifocal leukoencephalopathy) were noted.